Other immune therapy research has similarly focused on combination therapy, with anti‐PD‐1/TIM‐3 bi‐specific antibodies in clinical trial for solid tumors, including NSCLC (NCT03708328). The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.